Our clients rely on the knowledge, skills and expertise of NeuClone's team to provide the highest quality cell lines for the manufacturing of biological APIs. The NeuClone culture is centred upon generating the best cell lines in an atmosphere that is both friendly and driven.
Noëlle-Ann Sunstrom, PhD, MBA, FAICD
Chief Executive Officer
Dr Sunstrom has been the CEO of NeuClone since it was established in 2007.
Dr Sunstrum has over 15 years experience in the biopharmaceutical industry including more than 10 years of executive experience in biopharmaceutical companies. Dr Sunstrom has led teams in product development from laboratory to the market and founded and led two biotechnology companies in the area of CHO cell line development. Dr Sunstrom has held previous positions as CSO and Co-Founder of Acyte Biotech Pty Ltd as well as Deputy Director of both the CRC for Biopharmaceutical Research and the Bioengineering Centre at the University of New South Wales.
Russell J. Howard, PhD
Dr Howard joined NeuClone as Executive Chairman in January 2013. As a Senior executive with 15 years of CEO experience leading technology-based Life Science companies, most notably Maxygen Inc (NASDAQ: MAXY), Dr Howard has led corporate development strategies to generate over 30 products marketed worldwide and raised over $250 million on the U.S. public equity market. Howard is also the inventor of a rapid, inexpensive, human malaria diagnostic test marketed worldwide for 17 years. Russell has a breadth of technical experience in product discovery and development for pharmaceuticals and has published over 140 scientific publications in refereed journals and is an inventor on five issued patents.
Mr David W. Anstice
Advisor to the Board of Directors
David Anstice joined NeuClone as an Advisor to the Board of Directors in February 2013. Previously, Anstice served as Executive Vice President of Merck & Co. responsible for corporate strategy for Merck’s business in the U.S., Europe, Canada, Latin America, Japan, Asia and Australia. Anstice also served on the BIO (USA) Executive Committee for 9 years. David is currently non-Executive Director of CSL Ltd. (ASX:CSL) and Alkermes plc, Dublin, Ireland (NASDAQ: ALKS). Anstice received his Bachelor of Economics from the University of Sydney, Australia.
Mr Charles Summers, CPA
Chief Financial Officer
Mr Summers performs the role of chief financial officer at NeuClone. Summers has a CPA and has worked with a number of other life science companies.